Plain-English translation of NCT07312110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether D-serine, an amino acid naturally found in the body, can help slow down Parkinson's disease progression. Researchers want to see if giving this medication at different time points during treatment makes a difference in how the disease develops. You would receive both the medication and a placebo at different stages of the study.
Current Parkinson's treatments help manage symptoms but don't stop the disease from progressing over time. This study explores whether this medication might work differently — potentially slowing the underlying disease process itself, which could offer patients a new way to preserve their quality of life longer.
You likely qualify if…
You likely don't qualify if…
First, you'll go through a screening process where your Parkinson's medication is optimized and stabilized. Then you'll be randomly assigned to one of two groups and take either the medication or a placebo for 58 weeks total—with the timing differing between groups. After 32 weeks, your regular Parkinson's medications can be adjusted if needed. Once the treatment phase ends, you'll stop taking the study drug and return for visits over the next 12 weeks to see how you do.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Norway